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Phase II study of rhizoxin in squamous cell head and neck cancer
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Summary To test the anti-turnour activity o f rhizoxin in recurrent and/or metastatic squamous cell head and 
neck cancer, we performed a phase II study. Eligibility required histologically proven squamous cell head and 
neck cancer, Patients could only have received one prior chemotherapy. Patients were entered if WHO PS was 
< 2  and organ functions were normal. Treatment consisted of rhizoxin 1.5 -2 .0  mg m “ 2 i.v. bolus injection 
once every 3 weeks, Thirty-two patients entered the study. All were eligible, 31 were evaluable for toxicity and
25 for response, Toxicity mainly consisted o f pain at the tumour site and leucocytopenia. Mild asthenia and 
stomatitis were also observed, Two objective partial responses, lasting 7.5 and 3,5 months, were seen. Rhizoxin 
at this dose and schedule has minor activity in recurrent and/or metastatic squamous cell head and neck cancer.
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The incidence of head and neck cancer in Europe is about 35 
per 100 000 per year in males and 5 per 100 000 in females. 
The vast majority of head and neck tumours are of squamous 
cell type. Curative treatment for disease of limited extension 
consists of radiation therapy and/or surgery. The failure rate 
of curative treatment varies with the extension of the disease 
and the origin of the tumour. Five year survival rates may 
also vary considerably depending on the extension and 
primary site, with lowest values less than 25% and highest 
values more than 75%. Chemotherapy is used in the 
treatment of squamous cell carcinoma of the head and neck 
either as the only therapeutic modality for advanced or 
recurrent tumours or as part o f  a multimodality approach, 
The chemotherapy regimens most widely used consist of 
combinations of methotrexate and bleomycin, and more 
recently, eisplatin or other agents, with response rates in 
locally advanced disease equal or greater than 50%, but in 
metastatic disease only 10-25% .
The response and survival of squamous cell carcinoma of 
the head and neck to chemotherapy may be considerably 
influenced by characteristics of the patients and/or the 
tumour, such as performance status, prior therapy, site of 
origin of the tumour and possibly histological differentiation 
(Clavel and Mansour, 1991).
In view of the high recurrence rate after induction 
chemotherapy and the low response rate in metastatic 
disease, the screening o f potentially useful drugs in 
squamous cell carcinoma of the head and neck is warranted 
and might lead to improve current treatment of this frequent 
tumour,
Rhizoxin is a 16-membered macrocyclic lactone with 
antifiuigal activity (Iwasaki et a l , 1984; Kiyoto et al., 
1986). It is produced by and isolated from the pathogenic 
fungus Rhizopus chinensisy which causes rice seedling blight, 
The drug has a molecular weight of 625.8 and is poorly 
soluble (<  1 mg m l ' 1) in water and hydro-alcoholic vehicles, 
but very soluble (> 100  mg m l" 1) in organic solvents such as 
alcohols, dimethyl sulphoxide and chloroform. Rhizoxin has 
shown activity in vitro and in vivo in a wide variety of tumour 
models (Matsuda et a l., 1984; Hendriks et a l 1992). 
Rhizoxin inhibits the mitosis of tumour cells in a way
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similar to vincristine and maytansine (Tsuruo, 1986; 
Takahashi, 1987), with a resulting cell cycle block in the 
G2/M phase. Binding studies showed that rhizoxin bound to 
the vincristine binding site and not the colchicine binding site, 
inhibiting polymerisation of tubulin. The drug was also active 
in several cell lines resistant to vincristine (Tsuruo et a l , 
1986). In vitro studies have shown that an intermittent 
administration of the drug induced a significantly better 
tumour growth inhibition than a daily dose schedule 
(Hendriks et al., 1992),
In a phase I study using an intravenous bolus adminis­
tration patients were treated with doses ranging from 0,8 to 
2.6 mg m~2 single dose every 3 weeks (Bissett et a l 1992). 
The dose-limiting toxicities were mucositis, diarrhoea, 
leucopenia, neutropenia and thrombocytopenia. Other toxi­
cities observed were fever, peripheral neuropathy (PNP), 
hepatic toxicity, headache, rash and change in taste, all mild 
and infrequent. Alopecia was also noticed. All patients 
experienced mild to moderate local discomfort during the 
injection of rhizoxin, although phlebitis occurred in only 
three patients. Three patients with breast cancer showed an 
objective response. The dose recommended for phase II 
studies was 2,0 mg m “ 2 given every 3 weeks.
The EORTC Early Clinical Trials Group performed a 
phase II study in patients with metastatic or Iocoregionally 
advanced squamous cell cancer of the head and neck.
Patients and methods
Eligibility
Eligibility criteria included histologically or cytologically 
verified, uni- or bidimensionally measurable, locally ad­
vanced, unresectable or metastatic squamous cell carcinoma 
of the head and neck, WHO performance status < 2, age 
>18 years; and adequate bone marrow (WBC^4000 /¿I“ 1; 
platelets >  100 000 /¿l-"1)» hepatic and renal function.
Patients must not have received more than one 
chemotherapy regimen for advanced disease prior to entry 
in the study, while a minimum of 4 weeks was required 
between last dose of previous treatment and study treatment. 
Previous radiotherapy was permitted provided it did not 
involve the only measurable lesion, unless this lesion had 
newly arisen in a previously irradiated field. Informed 
consent had to be obtained and documented according to 
the local regulatory requirements and the rules followed at 
each institution.
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Treatment
Rhizoxin was supplied as vacuum white to off-white dried 
powder in 10 ml amber vials. Each vial contained 5 mg of 
rhizoxin, 25 mg of mannitol (USP)> and 25 mg ascorbic acid 
(USP). Rhizoxin vials were delivered in a duo-pack, which 
also contained special 2,5 ml sterile diluent vials containing 
80% (v/v) propylene glycol and 2 0 % (v/v) ethanol.
After reconstitution and after complete dissolution was 
obtained 2.5 ml of sterile water for injection had to be added. 
The resulting solution thus contained: rhizoxin I mg ml ’ 1 in 
40% propylene glycol (v/v), 10% ethanol (v/v) in sterile water 
for injection. Initially rhizoxin was administered at a dose of
2 mg m ” 2 by a single bolus i.v. injection once every 3 weeks. 
It was to be administered directly into the vein, not into a 
running drip, as it precipitates in saline and dextrose 
solutions. The cannula should be flushed through afterwards 
with 1 cc of the special diluent.
Treatment had to be delayed by I week if WBC and platelets 
at the scheduled day of retreatment were < 3.0 x 10131" 1 and/or
< 1 0 0  x 109 1.1 respectively. In this case the next course was to
be given at 75%. Dose reductions to 75% were also made if the 
proceeding course was complicated by a documented episode of 
either bleeding with thrombocytopenia or febrile neutropenia 
requiring hospitilisation.
For patients who developed >  grade 3 non-haematological 
toxicity, the decision to have their therapy reduced to 7 5 % or 
withheld dependend upon the investigator’s judgement. 
Patients whose treatment was delayed for more than 2 
weeks were removed from the study.
During the course of the study, because of observed side- 
effects, the starting dose of rhizoxin was amended to
1.5 mg i r r 2 once every 3 weeks for patients who had prior 
radiotherapy. In case of less than grade 3 haematological 
toxicity and less than grade 2  mucositis the dose should 
subsequently be increased to 2 . 0  mg m 2.
Table I Patient characteristics
*****
Follow-up studies
Prior to entry, history and physical examination were 
performed, as well as assessment of haemoglobin, WBC, 
differential, platelets, serum crcatininc and biochemistry 
including at least N a \  K \  C a2,\  albumin, bilirubin, 
ÀSAT, ÀLAT, alkaline phosphatase, and LDH. In addition 
urinalysis, chest radiograph and radiographies for turnout’ 
measurements were performed. D uring the study history, 
physical examination, haematology and biochemistry were 
repeated every three weeks. After the amendment regarding 
the starting dose, haematology parameters were taken 
weekly. Tumour measurements and the related diagnostics 
were repeated every two courses.
Evalua (hm
All pa tien Ls were eligible, one did not s ta r t  treatment. 
Toxicity was graded according to CTC criteria. Patients 
were scheduled to receive at least two doses o f rhizoxin» and 
to assess activity at least 14 evaluable cases were required. 
Response was assessed by repeated clinical and radiological 
examinations as appropriate, using W H O  criteria. Patients 
demonstrating evident tumour progression after 3 weeks were 
taken off study and classified as ‘early progression'. The 
duration of partial response or no change dated from the 
commencement of treatment until the documentation of 
progression. The duration of survival was dated from the 
initiation of treatment.
Results
A total of 32 patients were entered into the study. Patient 
characteristics are given in Table I. Thirty-one patients were 
evaluable for toxicity. Six patients could not be evaluated for 
response, all because of early treatment discontinuation due 
to  toxicity. This left 25 patients evaluable for response.
No, of patients 32
Eligible 32
Sex (M /F) 30/2
Age
M edian 60
R a nge (31-75)
W HO-PS
0
1
2
9
4M
I
Prior surgery 27
Prior radiotherapy 29
Prior chemotherapy 14
I !*■<
A total of 89 treatment doses were given with a median
number o f 2 (range 1..11). Responses are given in Table II.
Two partial remissions, assessed by CT scan, were observed 
and confirmed by extramural review. Response duration was
7.5 and 3.5 months respectively. The overall response rate 
regarding evaluable patients is 8 % (95% eon tide ncc interval 
1 -26% ). ThivS response rate is 6 % regarding all treated 
patients. One of these responses was documented in a 32- 
year-old patient suffering from a large ulcerated ccrvial 
recurrence o f a tongue carcinoma, Rhizoxin was started after 
documentation of disease progression during ca rbop la tin -  
5FU chemotherapy. An 82% tum our regression was observed 
during rhizoxin therapy. This response lasted for 10 weeks, 
The second responding patient was treated with neo-adjuvant 
chemotherapy and radiotherapy lor a large squamous cell 
carcinoma of the tongue, and by surgery and radiotherapy at 
local recurrence 1 year later. The patient then developed 
cervical lymph node metastases and obtained a partial 
remission, assessed by CT scan, with rhizoxin. All but one 
of the 17 courses of rhizoxin given to the responding patients 
were given at the dose of 1,5 mg n r ' 2.
The most intriguing si de-effect of rhizoxin was a severe 
pain at the tumour site, that could hardly be controlled by 
intravenous morphines* It occurred mainly in the first cohort 
of patients treated and led to the amendment in starting dose 
indicated above. Thirty-four courses were given at the dose of 
2 . 0  mg m *\ all others at lower doses. After lowering the 
starting dose the side-effect was no longer observed. In total 
it was seen in 9 of the 32 patients treated (28%), six of whom 
were taken off the study because o f this toxicity.
Further treatment was well tolerated. Haematological 
toxicity was moderate and consisted of leucoeytopenia 
grades 1 2 in 35 administrations (39%) and grades 3 4 in 
15 courses (17%), while thrombocytopenia grades 1 3 was 
noticed in three courses (3%). Although not required per 
protocol, in 82 of the 89 courses laboratory tests were 
peri brined weekly, so for this particular study the above data 
rclicet the actual haematological toxicity. L.eucocytopenia 
appeared to be short-lasting. Non-haematological toxicity 
consisted o f mild to moderate phlebitis in 23 courses (26%), 
asthenia in 24 courses (27%) and stomatitis in 28 courses 
[31%; six courses (7%) grades 3 4]. Alopecia was noted in 
26 patients (84%). In only six courses did patients experience 
(mainly mild) diarrhoea (7%). All other side-e fleets were 
infrequent,
Table II Responses
,  i .  * 1  ^  â ^ r r r »  -  i  *  : - • j * » *  t  * ,  , i ; « v  » ' ' M i  - m i  V «
Mo. of patients
*> * . t é
CR
PR
NC
PD
NE
Total
0
T
8
15
7
32
CR, complete response; PR, partial response; NC', no change; PD, 
progressive disease; NE, not evaluable.
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Discussion
Rhizoxin has an interesting preclinical profile of anti-tumour 
activity. A phase I study revealed neutropenia* thrombope- 
nia, mucositis and diarrhoea as dose-limiting toxicities 
(Bissett et ctL, 1992). In the presently reported phase II 
study, treatment was initially poorly tolerated due to a 
remarkably severe pain, occurring at tumour sites previously 
treated with radiotherapy and unrelievable by any analgetic 
treatment, including intravenous morphines, but reduction of 
the starting dose resulted in complete disappearance of this 
si de-effect. Similar observations were made in head and neck 
cancer patients treated with vinca alkaloids. The pathogenetic 
mechanism related to the observed pain in the tum our sites 
will need to be elucidated, This side-effect was not noted in 
patients who had undergone previous radiotherapy for other 
diseases, but in most of these diseases radiation doses were 
lower than the common dose used in the treatment o f head 
and neck cancer, W hether the radiation dose has any relation
to the observed side-effect cannot be stated for certain, 
because of the small sample size. Other reasons for poor 
tolerance were severe mucositis and febrile neutropenia in the 
first few patients treated at the initial starting dose. After 
reduction of the starting dose, treatment was well tolerated 
with a 56% occurrence of mainly uncomplicated leucocyto- 
penia, mild asthenia (27%) and stomatitis (31%). Thrombo­
cytopenia and diarrhoea, dose-limiting toxicities in the phase 
I study, were only seen in 3% and 7% of the head and neck 
cancer patients. These lower incidences could be partly 
related to the lower doses used in the present study.
Only two objective partial remissions (8 %) were achieved, 
Although the preclinical studies did not show any schedule 
dependency, other schedules may result in better locoregional 
tolerability and in theory may enable higher doses with 
higher response rates. This should first be explored in models 
attempting to unravel the mechanism behind the tumour 
pain.
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